|
市場調査レポート
商品コード
1672642
血漿由来医薬品市場：製品別、用途別、流通チャネル別、地域別Plasma Derived Medicine Market, By Product, By Application, By Distribution Channel, By Geography |
||||||
カスタマイズ可能
|
|||||||
| 血漿由来医薬品市場：製品別、用途別、流通チャネル別、地域別 |
|
出版日: 2025年02月19日
発行: Coherent Market Insights
ページ情報: 英文 156 Pages
納期: 2～3営業日
|
- 全表示
- 概要
- 目次
世界の血漿由来医薬品市場は、2025年には198億7,000万米ドルと推定され、2032年には327億7,000万米ドルに達すると予測され、2025年から2032年までの年間平均成長率（CAGR）は7.4%で成長する見込みです。
| レポート範囲 | レポート詳細 | ||
|---|---|---|---|
| 基準年 | 2024年 | 2025年の市場規模 | 198億7,000万米ドル |
| 実績データ | 2020年から2024年まで | 予測期間 | 2025年から2032年 |
| 予測期間：2025年-2032年 CAGR： | 7.40% | 2032年の価値予測 | 327億7,000万米ドル |
血漿由来医薬品は、ヒト血漿を原料として製造されます。これらの医薬品は、免疫不全疾患、出血性疾患、神経疾患など、さまざまな希少疾患の治療に使用されます。世界中で希少疾患の有病率が高まり、治療オプションが進歩することで、血漿由来治療薬の需要が高まる可能性があります。さらに、血漿誘導体に基づく革新的な治療法の開発に向けた政府および民間セクターによる投資の増加は、市場の成長を促進する可能性があります。しかし、血漿由来薬剤に関連するコストが高く、規制の枠組みが厳しいことが市場成長の妨げとなる可能性があります。エビデンスに基づく治療を重視する傾向の高まりと新興国市場の重点化は、近い将来、血漿由来薬プロバイダーにビジネスチャンスをもたらす可能性があります。
市場力学：
世界の血漿由来医薬品市場の成長は、希少な免疫疾患や出血性疾患の世界の有病率の上昇が牽引しています。免疫性血小板減少症、低ガンマグロブリン血症、神経疾患といった疾患の治療に血漿療法の採用が増加しており、市場成長の原動力となっています。ヘルスケア支出の増加と、血漿誘導体の製造をサポートする規制ガイドラインの進化も市場成長の原動力となります。革新的な分画技術の開拓や、市場参入企業による特殊なバイオプロセス基盤の開発は、血漿由来医薬品の製造を促進します。しかし、血漿採取や複雑な製造工程にかかるコストが高いため、血漿由来療法の迅速な商業化の妨げとなる可能性があります。安全性と有効性の評価に関する厳しい規制は、市場参入企業にとって課題となる可能性があります。アジアやラテンアメリカの新興諸国では、代替治療が限られているため需要が高まっており、近い将来、メーカーに新たなビジネスチャンスがもたらされる可能性があります。
本調査の主な特徴
本レポートでは、世界の血漿由来医薬品市場を詳細に分析し、2024年を基準年とした予測期間（2025-2032年）の市場規模（10億米ドル）と年間平均成長率（CAGR%）を掲載しています。
さまざまなセグメントにわたる潜在的な収益機会を解明し、この市場の魅力的な投資提案のマトリックスについて説明しています。
また、市場促進要因、抑制要因、機会、新製品の発売や承認、市場動向、地域別の展望、主要企業が採用する競争戦略などに関する重要な考察も提供しています。
世界の血漿由来医薬品市場における主要企業プロファイルを、企業ハイライト、製品ポートフォリオ、主要ハイライト、業績、戦略などのパラメータに基づいて掲載しています。
主要企業には、武田薬品工業、CSL Ltd.、Grifols S.A.、Octapharma AG、Kedrion S.p.A.などが含まれます。
本レポートからの洞察により、マーケティング担当者や企業の経営陣は、将来の製品発売、タイプアップ、市場拡大、マーケティング戦術に関する情報に基づいた意思決定を行うことができます。
世界の血漿由来医薬品市場レポートは、投資家、サプライヤー、製品メーカー、流通業者、新規参入者、財務アナリストなど、この業界の様々な利害関係者に対応しています。
利害関係者は、世界の血漿由来医薬品市場を分析する際に使用される様々な戦略マトリックスを通じて、意思決定を容易にすることができます。
目次
第1章 調査の目的と前提条件
- 調査目的
- 前提条件
- 略語
第2章 市場の展望
- レポートの説明
- 市場の定義と範囲
- エグゼクティブサマリー
第3章 市場力学、規制、動向分析
- 市場力学
- 影響分析
- 主なハイライト
- 規制シナリオ
- 製品の発売/承認
- PEST分析
- PORTERの分析
- 合併と買収のシナリオ
第4章 世界の血漿由来医薬品市場、製品別、2020年-2032年、（10億米ドル）
- 免疫グロブリン
- 凝固因子
- アルブミン
- その他
第5章 世界の血漿由来医薬品市場、用途別、2020年-2032年（10億米ドル）
- 骨盤内炎症性疾患（PID）
- 出血性疾患
- アルファ1アンチトリプシン欠乏症（AATD）
- 遺伝性血管性浮腫（HAE）
- 慢性炎症性脱髄性多発神経炎
- ギランバレー症候群
- 多巣性運動神経障害
- 肝臓疾患
- 原発性免疫血小板減少症
- 感染症
- その他の希少疾患
第6章 世界の血漿由来医薬品市場、流通チャネル別、2020年-2032年（10億米ドル）
- 病院薬局
- 小売薬局
- オンライン薬局
第7章 世界の血漿由来医薬品市場、地域別、2020年-2032年、（10億米ドル）
- 北米
- ラテンアメリカ
- 欧州
- アジア太平洋
- 中東
- アフリカ
第8章 競合情勢
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Octapharma AG
- Kedrion Biopharma
- LFB S.A.
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- HemaCare Corporation
- Sanquin Blood Supply Foundation
- Biotest AG
- Emergent BioSolutions Inc.
- Medac GmbH
- Scripps Laboratories
- BPL（Bio Products Laboratory）
- Fresenius Kabi AG
- Kamada Pharmaceuticals
第9章 アナリストの推奨事項
- 運命の輪
- アナリストの見解
- 一貫した機会マップ
第10章 参考文献と調査手法
- 参考文献
- 調査手法
- 出版社について
Global Plasma Derived Medicine Market is estimated to be valued at USD 19.87 Bn in 2025 and is expected to reach USD 32.77 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.4% from 2025 to 2032.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2024 | Market Size in 2025: | USD 19.87 Bn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: | 7.40% | 2032 Value Projection: | USD 32.77 Bn |
Plasma derived medicines are manufactured using human blood plasma as the raw material. These medicines are used for treating various rare diseases like immune deficiency disorders, bleeding disorders, neurological disorders and more. Growing prevalence of rare diseases across the globe and advancements in therapy options can boost demand for plasma derived therapies. Furthermore, rising investments by government and private sectors in developing innovative treatments based on plasma derivatives can drive the market growth. However, high costs associated with plasma derived medication and stringent regulatory frameworks can hamper the market growth. Increasing emphasis on evidence-based treatment and emerging markets in developing nations can offer opportunities for plasma derived medicine providers in the near future.
Market Dynamics:
Global plasma derived medicine market growth is driven by rising prevalence of rare immunological and bleeding disorders worldwide. Growing adoption of plasma therapies to treat conditions like immune thrombocytopenia, hypogammaglobulinemia and neurological disorders can drive the market growth. Increasing healthcare spending coupled with evolving regulatory guidelines supporting manufacture of plasma derivatives can also drive the market growth. Emergence of innovative fractionation techniques and development of specialized bioprocessing infrastructure by market players facilitates the production of plasma derived drugs. However, high costs involved in plasma collection and complex production processes can hamper the rapid commercialization of plasma derived therapy. Stringent regulations regarding safety and efficacy evaluation can pose challenges for market players. Growing demand in emerging Asian and Latin American countries due to limited availability of alternative treatments can offer novel opportunities for manufacturers in the near future.
Key features of the study:
This report provides in-depth analysis of the global plasma derived medicine market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global plasma derived medicine market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Takeda Pharmaceutical Company Ltd., CSL Ltd., Grifols S.A., Octapharma AG, and Kedrion S.p.A
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global plasma derived medicine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global plasma derived medicine market
Detailed Segmentation-
- Product Insights (Revenue, USD Bn, 2020 - 2032)
- Immunoglobulin
- Coagulation factors
- Albumin
- Others
- Application Insights (Revenue, USD Bn, 2020 - 2032)
- Pelvic Inflammatory Disease (PID)
- Bleeding Disorders
- Alpha-1 Antitrypsin Deficiency (AATD)
- Hereditary Angioedema (HAE)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Guillain-Barre Syndrome
- Multifocal Motor Neuropathy
- Liver Diseases
- Primary Immune Thrombocytopenia
- Infections
- Other Orphan Diseases
- Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Regional Insights (Revenue, USD Bn, 2020 - 2032)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Key Players Insights
- CSL Behring
- Takeda Pharmaceutical Company Limited
- Grifols, S.A.
- Octapharma AG
- Kedrion Biopharma
- LFB S.A.
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- HemaCare Corporation
- Sanquin Blood Supply Foundation
- Biotest AG
- Emergent BioSolutions Inc.
- Medac GmbH
- Scripps Laboratories
- BPL (Bio Products Laboratory)
- Fresenius Kabi AG
- Kamada Pharmaceuticals
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Global Plasma Derived Medicine Market, By Product
- Global Plasma Derived Medicine Market, By Application
- Global Plasma Derived Medicine Market, By Distribution Channel
- Global Plasma Derived Medicine Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Plasma Derived Medicine Market, By Product, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Immunoglobulin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Coagulation factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Albumin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
5. Global Plasma Derived Medicine Market, By Application, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Pelvic Inflammatory Disease (PID)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Bleeding Disorders
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Alpha-1 Antitrypsin Deficiency (AATD)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Hereditary Angioedema (HAE)
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Chronic Inflammatory Demyelinating Polyneuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Guillain-Barre Syndrome
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Multifocal Motor Neuropathy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Liver Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Primary Immune Thrombocytopenia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Other Orphan Diseases
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
6. Global Plasma Derived Medicine Market, By Distribution Channel, 2020-2032, (USD Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021- 2032
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
7. Global Plasma Derived Medicine Market, By Region, 2020 - 2032, (USD Bn)
- Introduction
- Market Share (%) Analysis, 2025,2028 & 2032, (USD Bn)
- Market Y-o-Y Growth Analysis (%), 2021 - 2032, (USD Bn)
- Regional Trends
- North America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country, 2020 - 2032, (USD Bn)
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, By Product, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Application, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032, (USD Bn)
- Market Size and Forecast, By Country/Sub-region, 2020 - 2032, (USD Bn)
- South Africa
- North Africa
- Central Africa
8. Competitive Landscape
- CSL Behring
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Takeda Pharmaceutical Company Limited
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Grifols, S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Octapharma AG
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Kedrion Biopharma
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- LFB S.A.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- ADMA Biologics, Inc.
- Bio Products Laboratory Ltd.
- China Biologic Products Holdings, Inc.
- Shanghai RAAS Blood Products Co., Ltd.
- HemaCare Corporation
- Sanquin Blood Supply Foundation
- Biotest AG
- Emergent BioSolutions Inc.
- Medac GmbH
- Scripps Laboratories
- BPL (Bio Products Laboratory)
- Fresenius Kabi AG
- Kamada Pharmaceuticals
9. Analyst Recommendations
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
10. References and Research Methodology
- References
- Research Methodology
- About us
